Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review

MD Ilie, A Vasiljevic, E Jouanneau… - Endocrine-related …, 2022 - erc.bioscientifica.com
Once temozolomide has failed, there is no recommended treatment option for pituitary
carcinomas and aggressive pituitary tumors. Immune-checkpoint inhibitors (ICIs) represent …
被引用次数：26 相关文章

Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review.

MD Ilie, A Vasiljevic, E Jouanneau… - Endocrine-related …, 2022 - europepmc.org
Once temozolomide has failed, there is no recommended treatment option for pituitary
carcinomas and aggressive pituitary tumors. Immune-checkpoint inhibitors (ICIs) represent …

Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review

MD Ilie, A Vasiljevic, E Jouanneau… - Endocrine-Related …, 2022 - cnrs.hal.science
Once temozolomide has failed, there is no recommended treatment option for pituitary
carcinomas and aggressive pituitary tumors. Immune-checkpoint inhibitors (ICIs) represent …

Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review

MD Ilie, A Vasiljevic, E Jouanneau… - Endocrine-related …, 2022 - pubmed.ncbi.nlm.nih.gov
Once temozolomide has failed, there is no recommended treatment option for pituitary
carcinomas and aggressive pituitary tumors. Immune-checkpoint inhibitors (ICIs) represent …

Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review

MD Ilie, A Vasiljevic, E Jouanneau… - Endocrine-Related …, 2022 - hal.science
Once temozolomide has failed, there is no recommended treatment option for pituitary
carcinomas and aggressive pituitary tumors. Immune-checkpoint inhibitors (ICIs) represent …